Amphastar Pharmaceuticals/$AMPH
1D1W1MYTD1Y5YMAX
Capital at risk
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
- Ticker
- $AMPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,976
- Headquarters
- Rancho Cucamonga, United States
- Website
- www.amphastar.com
AMPH Metrics
BasicAdvanced
$1.1B
15.03
$1.69
0.91
-
Price and volume
Market cap
$1.1B
Beta
0.91
52-week high
$29.52
52-week low
$16.65
Average daily volume
483K
Financial strength
Current ratio
2.397
Quick ratio
1.663
Long term debt to equity
0.881
Total debt to equity
0.896
Interest coverage (TTM)
6.32%
Profitability
EBITDA (TTM)
194.514
Gross margin (TTM)
47.68%
Net profit margin (TTM)
10.76%
Operating margin (TTM)
18.82%
Effective tax rate (TTM)
23.01%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.11%
Return on equity (TTM)
10.30%
Valuation
Price to earnings (TTM)
15.027
Price to revenue (TTM)
1.574
Price to book
1.4
Price to tangible book (TTM)
8.96
Price to free cash flow (TTM)
7.517
Free cash flow yield (TTM)
13.30%
Free cash flow per share (TTM)
3.372
Growth
Revenue change (TTM)
1.02%
Earnings per share change (TTM)
-37.04%
3-year revenue growth (CAGR)
10.51%
10-year revenue growth (CAGR)
10.53%
3-year earnings per share growth (CAGR)
-4.56%
10-year earnings per share growth (CAGR)
18.52%
What the Analysts think about AMPH
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
Analyst projections of the future price of Amphastar Pharmaceuticals stock.
Bulls say / Bears say
Second-quarter revenue rose 5% year on year, while gross margin increased to about 51%, helped by higher-margin launches including ipratropium, teriparatide and iron sucrose. Ipratropium alone contributed $8.4 million after its April launch. (Amphastar Pharmaceuticals)
The company expects further growth from its late-stage pipeline, with insulin aspart and its generic GLP-1 candidate targeted for launch in 2027. Success would add new products to the growth drivers already contributing to 2026 sales. (Stock Analysis)
BAQSIMI prescriptions grew about 17% year on year in the second quarter, pointing to stronger underlying demand even though lower net pricing reduced reported sales. Continued prescription growth could support the franchise if pricing pressures ease. (The Motley Fool)
Competition is eroding established products: glucagon sales fell 42% in the second quarter, with both lower prices and weaker volumes contributing to the decline. Lower average selling prices also weighed on BAQSIMI and epinephrine multi-dose vials. (Amphastar Pharmaceuticals)
An FDA warning letter at the IMS facility creates execution and compliance risk. Management expects $2 million to $3 million of additional quarterly remediation costs for several quarters and a slight slowing of sales from the site. (The Motley Fool)
Profitability weakened despite revenue growth: first-half net income fell to $36.8 million from $56.3 million a year earlier, while operating income also declined. Continued expense growth could make it harder for new-product sales to translate into stronger earnings. (Amphastar Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
AMPH Financial Performance
Revenues and expenses
AMPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
AMPH News
AllArticlesVideos
Funds containing AMPH
AllUSDGBPEUR
Fund name | Fund size | $AMPH weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.05% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.